National Service Hotline
0538-8260963
News Center
Current Location: Index > News Center >
Eastwud Pharmaceutical has completed the benchmarking analysis against EU GMP and FDA cGMP standards.
Release time:2026/1/17 Article source: This website
  From January 14 to 16, 2026, Eastwud Pharmaceutical (Shandong) Co., Ltd. joined hands with SGS (Societe Generale de Surveillance S.A.), an authoritative third-party organization, to launch an in-depth analysis project aligned with EU GMP and FDA cGMP standards.
  Taking EU GMP and FDA cGMP as the benchmark, this project conducted a comprehensive and professional comparative analysis focusing on core dimensions including hardware equipment configuration, equipment operational compliance, quality management processes, and document systems. Through systematic benchmarking, the company accurately identified room for optimization in its existing systems, achieved dual upgrades in compliance and standardization, and further consolidated the foundation for its international operations.

  The smooth advancement of this project is not only an important practice for Eastwud Pharmaceutical to deepen the construction of its compliance system, but also a crucial step for the company to expand from its domestic layout to the global market, laying a solid compliance foundation for its subsequent international business development.



NEWS CENTER
CONTACT US

Dongwu Pharmaceutical (Shandong) Co., Ltd

Phone:0538-8260963

Email:eastwud@163.com

Address: 300 meters west of the intersection of Zhongtianmen Street and Qudong Road in Daiyue District, Tai'an City (within Tai'an Zhongzhi Life and Health Industry Park)